Company stock · NASDAQ NMS - GLOBAL MARKET · USD

OBIO

Orchestra Biomed Holdings Inc

$5.59

Today

+$0.12+2.19%

vs yesterday’s close

Live price

Opened at: $5.46
Day high: $5.66
Day low: $5.39
Yesterday’s close: $5.47

Industry: Health Care
Market value: $336.0 million
Number of shares: 60.1 million
Country: US
Went public: Aug 4, 2020
Exchange: NASDAQ NMS - GLOBAL MARKET
Website: orchestrabiomed.com
Next earnings: 2026-11-16 · analysts’ expected profit per share $-0.41

Compare →Earnings calendar →

Price chart Pro

Loading chart…

Company briefing

What OBIO is

Plain English context — why the name shows up in the news, and what to watch next.

In plain English

Orchestra Biomed Holdings Inc. develops and commercializes cardiovascular therapies, including its AVIM Therapy and Virtue® SAB devices,…

Recent headlines

Live company news for OBIO — each headline includes a ClearTape brief in plain English; open the original for the full story.

12 Health Care Stocks Moving In Friday's After-Market SessionIn brief
The headline lists 12 health care stocks that moved in Friday’s after‑market session. It highlights Pomdoctor’s shares rising 25.6% to $1.47 and GeneDx Holdings’ shares up 8.72%, but no further details are provided.
Benzinga · Oct 23, 2026
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SABIn brief
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc.
Yahoo · Oct 22, 2026
OpenAI acquires Orchestra Bio to boost drug development AI, Axios reportsIn brief
OpenAI has bought Orchestra Bio, a startup that builds AI agents for drug development. The acquisition is reported by Axios and noted by Investing.com.
Yahoo · Oct 20, 2026
Orchestra BioMed Has A Clearer Trial Timeline But A Demanding ValuationIn brief
Orchestra BioMed’s stock is rated Hold at $5.72 ahead of its hypertension pacemaker trial data expected in Q2 2027. The company’s valuation is described as demanding.
SeekingAlpha · Oct 15, 2026

Latest on this name

Insights & deeper context

1 recent card — open any for the full deeper dive.

CompanyShort-termNeutralDays to weeksBenzingaOBIO SFNC CAT META

This Meta Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

In brief

Analysts are upbeat on SFNC, OBIO, CAT, META, and SNPS, lifting targets and ratings.

Open card →

Company reports

Official filings (US SEC and linked cards)

No filings here yet

Official report cards for OBIO will show up here when available.

Broad market indexes (like the S&P 500, a basket of 500 large US companies) are shown through popular funds that track them (for example SPY). Company profile and prices use live market data when available.